Tuning of G-CSFR signaling by de novo-designed agonists

Area of Science:

• Biochemistry and Molecular Biology
• Drug Discovery and Development
• Hematology and Stem Cell Biology

Background:

• Cytokine-based therapies are crucial for modulating hematopoietic stem cell functions.
• Granulocyte-colony stimulating factor receptor (G-CSFR) signaling is key for stem cell proliferation and differentiation.
• Current cytokine therapies lack precise control over receptor activation and downstream signaling.

Purpose of the Study:

• To design and characterize novel agonists that modulate G-CSFR activity.
• To investigate the impact of varying receptor-binding affinity and dimerization geometry on G-CSFR signaling.
• To develop therapeutic agents with enhanced specificity and stability for hematopoietic stem cell manipulation.

Main Methods:

• Rational design of G-CSFR agonists with altered binding affinities and dimerization properties.
• Characterization of agonist-receptor interactions, including binding kinetics and thermostability.
• Analysis of downstream signaling pathways (e.g., signal transduction, gene expression) and cellular responses (proliferation vs. differentiation).

Main Results:

• Achieved hyper-thermostable designed agonists that effectively compete with the native ligand (G-CSF).
• Demonstrated that designed agonists bias cells towards granulopoietic differentiation, suppressing proliferation.
• Observed differential modulation of signaling kinetics, amplitudes, and gene expression patterns, with selective activation of hematopoietic gene sets and minimal immunomodulatory effects.

Conclusions:

• Designed G-CSFR agonists offer a powerful strategy for dissecting complex receptor signaling.
• These novel agonists exhibit enhanced specificity, stability, and functional bias compared to native G-CSF.
• The findings open new therapeutic avenues for engineered cytokines in treating hematopoietic disorders and enhancing stem cell therapies.